{
    "clinical_study": {
        "@rank": "143072", 
        "acronym": "MCT", 
        "arm_group": [
            {
                "arm_group_label": "Metacognitive Therapy", 
                "arm_group_type": "Experimental", 
                "description": "Individuals randomly assigned to the metacognitive therapy group will undergo group metacognitive therapy  for generalized anxiety disorder.. Individuals will undergo 8 sessions of group therapy lasting approximately 90 minutes."
            }, 
            {
                "arm_group_label": "Mindfulness Meditation Therapy", 
                "arm_group_type": "Experimental", 
                "description": "Individuals randomly assigned to the mindfulness meditation therapy group will undergo group mindfulness meditation therapy for generalized anxiety disorder. Individuals will undergo 8 sessions of group therapy lasting approximately 90 minutes."
            }
        ], 
        "brief_summary": {
            "textblock": "The study will examine the effectiveness of group metacognitive therapy in comparison with\n      group meditation therapy, in patients with Generalised Anxiety Disorder. Individuals will be\n      randomly assigned to either meditation or metacognitive therapy and undergo 8 group therapy\n      sessions of their respective treatment condition."
        }, 
        "brief_title": "A Comparison of Metacognitive Group Therapy Versus Mindfulness Meditation Therapy in Generalized Anxiety Disorder", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Generalized Anxiety Disorder", 
        "condition_browse": {
            "mesh_term": "Anxiety Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  individual's score on the Generalised Anxiety Disorder Questionnaire (GAD-Q).\n\n          -  individuals who meet the DSM-IV (Diagnostic and Statistical Manual) criteria for\n             generalized anxiety disorder\n\n        Exclusion Criteria:\n\n          -  Individuals with major depressive disorder\n\n          -  Individuals who report suicidality\n\n          -  Individuals with a brain injury or neurological insult\n\n          -  Individual who currently engage in substance abuse\n\n          -  Individuals with bipolar disorder\n\n          -  Individuals with psychotic symptoms\n\n          -  Individuals who cannot converse or read English"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02096484", 
            "org_study_id": "UM145073"
        }, 
        "intervention": [
            {
                "arm_group_label": "Metacognitive Therapy", 
                "intervention_name": "Group Metacognitive Therapy", 
                "intervention_type": "Behavioral", 
                "other_name": "MCT"
            }, 
            {
                "arm_group_label": "Mindfulness Meditation Therapy", 
                "intervention_name": "Mindfulness Meditation Therapy", 
                "intervention_type": "Behavioral", 
                "other_name": "MMT"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Metacognitive therapy", 
            "mindfulness meditation therapy", 
            "group therapy", 
            "generalized anxiety disorder", 
            "Group Based Metacognitive Therapy", 
            "Group Based Mindfulness Meditation Therapy"
        ], 
        "lastchanged_date": "March 21, 2014", 
        "location": {
            "contact": {
                "email": "adrian.wells@manchester.ac.uk", 
                "last_name": "Adrian Wells, PhD Clinical Psychology", 
                "phone": "+44 (0)161 276 5399"
            }, 
            "facility": {
                "address": {
                    "city": "Manchester", 
                    "country": "United Kingdom", 
                    "state": "Lancashire", 
                    "zip": "M23 9LT"
                }, 
                "name": "The Rawnsley Building, Manchester Royal Infirmary, Oxford Road"
            }, 
            "investigator": {
                "last_name": "Adrian Wells, PhD Clinical Psychology", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Comparison of Group Metacognitive Therapy Versus Mindfulness Meditation Therapy in Generalized Anxiety Disorder", 
        "overall_contact": {
            "email": "adrian.wells@manchester.ac.uk", 
            "last_name": "Adrian Wells, PhD in Clinical Psychology", 
            "phone": "+44 (0)161 276 5399"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Manchester", 
                "last_name": "Lora Capobianco", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Manchester", 
                "last_name": "James Thompson", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: University of Manchester Research Ethics Committee", 
                "United Kingdom: Manchester Mental Health and Social Care Trust"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome measure will be the Penn State Worry Questionnaire (PSWQ). This will be administered routinely to participants. The Penn State Worry Questionnaire is a 16-item measure of pathological worry. Participants indicate how typically tendencies to worry apply to them on a 5-point likert scale.", 
            "measure": "Change in amount of worry over 8 weeks of treatment measured by the Penn State Worry Questionnaire (PSWQ)", 
            "safety_issue": "No", 
            "time_frame": "Administered at all treatment sessions ( once a week for 8 weeks) by the study investigators. It will also be administered once at 6 months and 12 months follow up following treatment completion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02096484"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Manchester", 
            "investigator_full_name": "Adrian Wells", 
            "investigator_title": "Professor of Clinical & Experimental Psychopathology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The State-Trait Anxiety Inventory (STAI) measures trait and state anxiety, and can be used to diagnose anxiety and to distinguish it from depressive syndromes(Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983).", 
                "measure": "Change in anxiety levels over 8 weeks of treatment measured by the Speilberg Trait Anxiety Inventory (STAI)", 
                "safety_issue": "No", 
                "time_frame": "This will be administered in the first and last treatment session (week 1 and week 8) by the study investigators, and once at 6 months and 12 months follow up following treatment completion"
            }, 
            {
                "measure": "Change in depression over 8 weeks of treatment measured by Beck Depression Inventory (BDI)", 
                "safety_issue": "No", 
                "time_frame": "This will be administered in the first and last treatment session (week 1 and week 8) by the study investigators, and once at 6 months and 12 months follow up following treatment completion"
            }, 
            {
                "measure": "Change in anxiety levels over 8 weeks of treatment measured by the Beck Anxiety Inventory (BAI)", 
                "safety_issue": "No", 
                "time_frame": "This will be administered in the first and last treatment session (week 1 and week 8) by the study investigators, and once at 6 months and 12 months follow up following treatment completion"
            }, 
            {
                "description": "The Metacognitions Questionnaire (MCQ-30) will be used to assess five domains of metacognitive beliefs. The five subscales include positive beliefs about worry, negative beliefs about uncontrollability and danger, cognitive confidence, negative beliefs about not controlling thoughts, and cognitive self-consciousness.", 
                "measure": "Change in metacognitions over 8 weeks of treatment measured by the Metacognitions Questionnaire (MCQ)", 
                "safety_issue": "No", 
                "time_frame": "This will be administered in the first and last treatment session (week 1 and week 8) by the study investigators, and once at 6 months and 12 months follow up following treatment completion"
            }, 
            {
                "description": "The GAD-Q is a nine item self-report questionnaire that is designed to be an initial screen for the presence of generalized anxiety disorder.", 
                "measure": "Change in symptoms of generalized anxiety disorder over 8 weeks of treatment measured by the generalized anxiety disorder questionnaire (GADQ)", 
                "safety_issue": "No", 
                "time_frame": "First completed prior to week 1 of treatment.This will be administered in the first and last treatment session (week 1 and week 8) by the study investigators, and once at 6 months and 12 months follow up following treatment completion"
            }
        ], 
        "source": "University of Manchester", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Manchester", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}